1. S31 Dupilumab reduces severe exacerbations across baseline disease characteristics in patients with elevated baseline type 2 biomarkers: the LIBERTY ASTHMA QUEST study. (12th November 2019) Authors: Busse, WW; Muñoz, X; Casale, TB; Paggiaro, P; Castro, M; Tohda, Y; Rice, MS; Deniz, Y; Rowe, P; Amin, N; Teper, A Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S127 Relation between change in type 2 biomarker levels and efficacy outcomes in patients with asthma treated with dupilumab. (11th November 2022) Authors: Pavord, ID; Deniz, Y; Casale, T; Corren, J; FitzGerald, JM; Altincatal, A; Gall, R; Pandit-Abid, N; Radwan, A; Jacob-Nara, JA; Rowe, PJ; Busse, WW Journal: Thorax Issue: Volume 77(2022)Supplement 1 Page Start: A78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗